Citius Oncology (NASDAQ:CTOR) Stock Price Up 39.8% – Here’s What Happened

Shares of Citius Oncology, Inc. (NASDAQ:CTOR) were up 39.8% on Monday . The stock traded as high as $1.17 and last traded at $0.93. Approximately 70,080,356 shares were traded during trading, an increase of 5,249% from the average daily volume of 1,310,223 shares. The stock had previously closed at $0.67.

Citius Oncology Trading Down 7.0 %

The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34. The business’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.14.

Citius Oncology (NASDAQ:CTOR) last posted its quarterly earnings results on Friday, February 14th. The company reported ($0.09) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Citius Oncology stock. IFP Advisors Inc increased its position in Citius Oncology, Inc. (NASDAQ:CTOR) by 173.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,215 shares of the company’s stock after acquiring an additional 14,080 shares during the period. IFP Advisors Inc’s holdings in Citius Oncology were worth $26,000 as of its most recent SEC filing. Institutional investors own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.